to INR3b from INR2.1b in 1QFY18. PAT of INR4.2b was broadly in line. Strong recovery in domestic business; key approvals to drive US growth: Domestic business grew 12% YoY (on a like to like basis, GST-adjusted growth was at 19% YoY) and ~30% QoQ due to channel refilling post GST. Channel inventory is still lower by ~10 days v/s GST levels. CIPLA expects to cover 5-6 days in 2H. US sales declined 3% YoY in 2QFY18. We expect US business growth to be driven by ramp-up of Sevelamer (launched recently), and key upcoming approvals such as Nano-paclitaxel and Albuterol MDI....